EMA's 'ok' to a new vaccine against Covid

The European Medicines Agency (EMA) authorized this Thursday the VidPrevtyn Beta vaccine, developed by the French laboratory Sanofi Pasteuras a dose of booster against COVID-19 in already vaccinated adults with an adenoviral vector mRNA preparation.

The EMA began evaluating Sanofi Pasteur's license application last March, but now its experts have concluded that they have sufficiently solid data on the quality, safety and immunogenicity of the vaccine to recommend its marketing authorization in the Union. European (EU).

“A booster dose of VidPrevtyn Beta is expected to be at least as effective as Comirnaty (trade name of Pfizer's vaccine) to restore protection against COVID-19, ”said the EMA.

This vaccine is based on a laboratory-grown version of the spike protein found on the surface of the Beta variant of the SARS-CoV-2 virus and contains an "adjuvant", a substance that helps strengthen immune responses to the vaccine.

Side effects

The most common side effects observed with this vaccine were injection site pain, headache, muscle or joint pain, malaise and chills but usually these were light Y they disappear in a couple of days after vaccination.

The EMA will now send its recommendations to the European Comissionwho is who has the last word on the authorization of vaccines in the European Union.

and it was authorized that of Sanofi Pasteur, theThe EU would have vaccines for COVID-19 developed by a total of seven pharmaceutical companies (Pfizer, Valneva, Novavax, Moderna, AstraZeneca and Janssen), although the EMA also keeps the data of three other vaccines under continuous review: the Spanish Hipra, the Russian Sputnik and the Chinese Vero Cell, which have not yet been able to apply for their license.

The one that has already requested the support of the EMA for a European license is the SK Chemicals laboratory for its Skycovion vaccine, but it is still being studied and there is no date for its approval.

Leave a Reply

Your email address will not be published. Required fields are marked *

Go up